On Monday, stocks closed out January on a higher note, even though indexes show a loss for the month as a whole. The market gained a measure of optimism from large merger deals and traded higher all day. The Centient Biotech 200 gained 41.82 points to 3384.06, a 1.25% rise, while the NYSE Composite was .82% higher and the Nasdaq climbed 1.31%. We look at New River Pharma, the best-performing IPO of 2004, which inked a commercialization deal, Wyeth, which missed its earnings target, Noven, which got good news from the FDA, and VaxGen, which will stay on the pink sheets for most of this year...
